 Valneva SE NASDAQ: VALN is trading significantly higher Wednesday following results from an initial laboratory study, which demonstrated that serum antibodies induced by three doses of Valnevas COVID-19 vaccine candidate, VLA2001, neutralize the omicron variant. Samples from 30 participants in the Phase 12 trial of Valnevas COVID-19 candidate were used in a pseudovirus assay to analyze neutralization of the ancestral SARS-CoV-2 virus as well as the delta and omicron variants. 